Tegsedi 2021 U.S. PROMOTIONAL AUDIT REPORT

Published July 2022 • 32 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Tegsedi through reportable promotional activity in 2021 and how does this compare to its peer set in the HATTR Amyloidosis market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Akcea and Sobi’s depth of coverage vary within key specialties (e.g., Nursing, Neurology, Cardiology, Physician Assistant, Interventional Cardiology, Internal Medicine, and Transplant Cardiology) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Tegsedi throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Tegsedi in 2021?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 1,360 paid interactions across 950 physicians made on behalf of Tegsedi were carefully examined to support our analysis. In addition, interaction data from 2 peer products (e.g. Onpattro and Vyndaqel ) was leveraged to provide benchmarking and market insights.